A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses and Multiple Dose of HSK31679 in Healthy Volunteers and Subjects With Elevated LDL-C
Latest Information Update: 08 Jan 2024
At a glance
- Drugs HSK 31679 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 01 Jan 2024 Status changed from recruiting to completed.
- 13 Sep 2022 New trial record